布罗利祖马布加化学疗法治疗晚期和复发性宫癌:根据随机化KEYNOTE-826研究中bevacizumab使用的最终分析
概括
布罗利祖马布加化疗改善了宫癌患者的存活率,无论使用贝瓦西祖马布. 在KEYNOTE-826试验中,这种组合疗法在各子组中显示出可管理的安全性.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 临床试验 临床试验
背景情况:
- 基诺特-826试验表明,布罗利祖马布加化疗 (±贝瓦齐祖马布) 改善了晚期宫癌的整体存活率 (OS) 和无进展存活率 (PFS).
- 这项分析探讨了基于bevacizumab使用的子组的疗效和安全性.
研究的目的:
- 为了评估 pembrolizumab加化学疗法与或没有bevacizumab在患有持久性,复发性或转移性宫癌的患者的疗效.
- 为了评估由bevacizumab使用定义的子组的结果.
主要方法:
- 晚期宫癌的成年患者接受了pembrolizumab或安慰剂加化学疗法 (±bevacizumab).
- 随机,双盲,安慰剂对照试验 (NCT03635567) 具有双重主要终点的OS和PFS.
- 在使用贝瓦齐祖马布和不使用贝瓦齐祖马布的小组中分析结果,使用危险比率 (HR) 和95%置信区间 (CI).
主要成果:
- 布罗利祖马布加化学疗法在接受贝瓦齐祖马布治疗和不接受贝瓦齐祖马布治疗的子组中都显示出改善了PFS和OS.
- 对于PFS和OS的HRs在所有子组中都偏爱pembrolizumab,包括PD-L1阳性和全新人群.
- 与治疗相关的≥3级不良事件在74.0% (pembrolizumab + bevacizumab) 和66.8% (安慰剂 + bevacizumab) 的患者中被观察到.
结论:
- 布罗利祖马布加化学疗法在患有持续性,复发性或转移性宫癌的患者中提供了长期的PFS和OS,而不管贝瓦西祖马布的使用情况如何.
- 布罗利祖马布加化疗的安全性概况在各个子组之间是可管理的.
- 这种组合疗法在治疗晚期宫癌方面取得了重大进展.
更多相关视频
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
11.4K
07:42Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
Published on: February 7, 2021
4.8K
相关概念视频
Tumor Immunotherapy
488
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
488
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Cancer Vaccines
342
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
342
Cancer Survival Analysis
328
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
328
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
151
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
151
